Progress or lack of progress in hospitalized heart failure.

about

Steps forward in regulatory pathways for acute and chronic heart failure.Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.

P2860

Q38322538-D90F61E8-8C5E-4DC3-BDBE-64FA16E6635F Q39024503-B468501B-868E-41F3-9223-63AB0F3E35FA

P2860

Progress or lack of progress in hospitalized heart failure.

Item

http://www.wikidata.org/entity/Q45904891

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Progress or lack of progress in hospitalized heart failure.

@en

Progress or lack of progress in hospitalized heart failure.

@nl

type

Item

label

Progress or lack of progress in hospitalized heart failure.

@en

Progress or lack of progress in hospitalized heart failure.

@nl

prefLabel

Progress or lack of progress in hospitalized heart failure.

@en

Progress or lack of progress in hospitalized heart failure.

@nl

P1476

Progress or lack of progress in hospitalized heart failure.

@en

P2093

Muthiah Vaduganathan

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of nesiritide in patients with acute decompensated heart failure

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial

Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial.

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.

Acute heart failure syndromes: current state and framework for future research.

Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure.

P304

1079-1083

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1586/14779072.2013.827465

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gregg C. Fonarow

Mihai Gheorghiade

Javed Butler

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257201858

http://www.w3.org/2001/XMLSchema#string

P698

24073673

http://www.w3.org/2001/XMLSchema#string

P921

hospitalization

Progress or lack of progress in hospitalized heart failure.

about

P2860

P2860

Progress or lack of progress in hospitalized heart failure.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921